POP-OUT | CLOSE

An Information Portal to 105339 Biological Macromolecular Structures

 
Gefitinib
 
IRE is found in 6 entries
IRE
  •   Chemical Component Summary   Hide
    Name Gefitinib
    Identifiers 3-chloro-4-fluoro-N-[(4Z)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(1H)-ylidene]aniline
    N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)-1H-quinazolin-4-imine
    Formula C22 H24 Cl F N4 O3
    Molecular Weight 446.90 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key XGALLCVXEZPNRQ-UHFFFAOYSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00317   (Stereoisomeric match)
    Name Gefitinib
    Groups
    • approved
    • investigational
    Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia]
    Synonyms
    • 4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
    • Gefitinib
    • Iressa
    • N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
    • ZD 1839
    Brand names Iressa
    Affected organism Humans and other mammals
    Indication For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
    Pharmacology Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.
    Mechanism of action Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation.
    Route of administration Oral
    ATC-Code L01XE02
    AHFS-Code 10:00.00
    CAS number 184475-35-2
    Targets
    Name Sequence search Pharmacological action Actions
    Epidermal growth factor receptor   Search  yes antagonist
     
Ligand Image